UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Nguyen TD
(2022)
Genetic heterogeneity and subtypes of major depression.
in Molecular psychiatry
Nguyen TNM
(2022)
Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer's disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies.
in Alzheimer's research & therapy
Nguyen TNM
(2022)
Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: results from two large cohorts with new-user design.
in Alimentary pharmacology & therapeutics
Ni G
(2019)
The genetic relationship between female reproductive traits and six psychiatric disorders.
in Scientific reports
Ni G
(2018)
Age at first birth in women is genetically associated with increased risk of schizophrenia.
in Scientific reports
Ni JJ
(2021)
Assessing causal relationship from gut microbiota to heel bone mineral density.
in Bone
Ni JJ
(2022)
Mendelian randomization study of causal link from gut microbiota to colorectal cancer.
in BMC cancer
Nicolopoulos K
(2020)
Association between habitual coffee consumption and multiple disease outcomes: A Mendelian randomisation phenome-wide association study in the UK Biobank.
in Clinical nutrition (Edinburgh, Scotland)
Niedzwiedz CL
(2020)
Depressive symptoms, neuroticism, and participation in breast and cervical cancer screening: Cross-sectional and prospective evidence from UK Biobank.
in Psycho-oncology
Nielsen JB
(2018)
Genome-wide Study of Atrial Fibrillation Identifies Seven Risk Loci and Highlights Biological Pathways and Regulatory Elements Involved in Cardiac Development.
in American journal of human genetics
Ning K
(2021)
Improving brain age estimates with deep learning leads to identification of novel genetic factors associated with brain aging.
in Neurobiology of aging
Ning K
(2020)
Association of relative brain age with tobacco smoking, alcohol consumption, and genetic variants.
in Scientific reports
Ning K
(2020)
Parity is associated with cognitive function and brain age in both females and males.
in Scientific reports
Ning Z
(2020)
High-definition likelihood inference of genetic correlations across human complex traits.
in Nature genetics
Niroula A
(2021)
Distinction of lymphoid and myeloid clonal hematopoiesis.
in Nature medicine
Niu PP
(2022)
Higher Circulating Vitamin D Levels Are Associated With Decreased Migraine Risk: A Mendelian Randomization Study.
in Frontiers in nutrition
Norbury R
(2020)
Diurnal Preference and Grey Matter Volume in a Large Population of Older Adults: Data from the UK Biobank
in Journal of Circadian Rhythms
Norbury R
(2019)
Chronotype, depression and hippocampal volume: cross-sectional associations from the UK Biobank.
in Chronobiology international
Nounu A
(2022)
Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study.
in Breast cancer research : BCR
Nouwen A
(2021)
Measurement invariance testing of the patient health questionnaire-9 (PHQ-9) across people with and without diabetes mellitus from the NHANES, EMHS and UK Biobank datasets.
in Journal of affective disorders
Nowak C
(2020)
Kidney Disease Biomarkers Improve Heart Failure Risk Prediction in the General Population.
in Circulation. Heart failure
Null M
(2022)
RAREsim: A simulation method for very rare genetic variants.
in American journal of human genetics
Nusinovici S
(2022)
Retinal photograph-based deep learning predicts biological age, and stratifies morbidity and mortality risk.
in Age and ageing
Nyberg ST
(2022)
Association of alcohol use with years lived without major chronic diseases: A multicohort study from the IPD-Work consortium and UK Biobank.
in The Lancet regional health. Europe
Nyberg T
(2023)
CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer
in Journal of Clinical Oncology
Nøst TH
(2021)
Systemic inflammation markers and cancer incidence in the UK Biobank.
in European journal of epidemiology
O'Connell KS
(2021)
Association between complement component 4A expression, cognitive performance and brain imaging measures in UK Biobank.
in Psychological medicine
O'Connor MJ
(2022)
Recessive Genome-Wide Meta-analysis Illuminates Genetic Architecture of Type 2 Diabetes.
in Diabetes
O'Donnell J
(2020)
Self-reported and objectively measured physical activity in people with and without chronic heart failure: UK Biobank analysis.
in Open heart
O'Donoghue M
(2022)
The Oxford Brain Health Clinic: Protocol and Research Database
O'Farrell F
(2022)
Molecular Alterations Caused by Alcohol Consumption in the UK Biobank: A Mendelian Randomisation Study.
in Nutrients
O'Halloran R
(2020)
BMI and Cause-Specific Hospital Admissions and Costs: The UK Biobank Cohort Study.
in Obesity (Silver Spring, Md.)
O'Mara TA
(2018)
Identification of nine new susceptibility loci for endometrial cancer.
in Nature communications
O'Nunain K
(2022)
A lifecourse mendelian randomization study highlights the long-term influence of childhood body size on later life heart structure
in PLOS Biology
O'Sullivan F
(2018)
Annual Ambient UVB at Wavelengths that Induce Vitamin D Synthesis is Associated with Reduced Esophageal and Gastric Cancer Risk: A Nested Case-Control Study.
in Photochemistry and photobiology
Obesity JO
(2022)
Retracted: Measures of Adiposity and Risk of Testing Positive for SARS-CoV-2 in the UK Biobank Study.
in Journal of obesity
Oguntade A
(2022)
Body composition and heart failure subtypes in the UK Biobank: a prospective study of 500,000 adults
in European Heart Journal
Ohi K
(2022)
Shared genetic basis between reproductive behaviors and anxiety-related disorders.
in Molecular psychiatry
Ojavee SE
(2021)
Genomic architecture and prediction of censored time-to-event phenotypes with a Bayesian genome-wide analysis.
in Nature communications
Ojavee SE
(2022)
Liability-scale heritability estimation for biobank studies of low-prevalence disease.
in American journal of human genetics
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |